Inmune Bio, Inc. (INMB) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US45782T1051
Inmune Bio, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 50,000.00 USD |
| Operating income | -47.38 m USD |
| EBIT | -45.93 m USD |
| Net income | -45.93 m USD |
| Diluted EPS – continuing operations | -1.86 USD |
Full history since 2015, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Inmune Bio, Inc.
INmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, which is in Phase II for the treatment of breast cancer. It provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression; and CORDstrom, a cell suspension for intravenous infusion or injection comprising aseptic, allogeneic, and pooled HucMSCs. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; GOSH; and University of Pittsburg. The company was incorporated in 2015 and is headquartered in Boca Raton, Florida.
More stocks
- Viscount Mining Corp. (VML.V)
- Cohen & Co Inc. (COHN)
- LeonaBio, Inc. (LONA)
- RESERVE PETROLEUM CO (RSRV)
- TuSimple Holdings Inc. (TSPH)
- DMS Propertindo Tbk PT (KOTA.JK)
- SCYNEXIS INC (SCYX)
- Laser Photonics Corp (LASE)
- VNUE, Inc. (RDCT)
- PFS Bancorp, Inc. (PFSB)
- Brand Engagement Network Inc. (BNAI)
- OneMedNet Corp (ONMD)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.